Peter Attia hosts neuroscientist Dr. Lisa Mosconi, director of the Women's Brain Initiative at Weill Cornell Medicine and pioneer in brain imaging for Alzheimer's disease. Mosconi leads research on how sex differences, particularly menopause and hormonal transitions, shape brain aging and dementia risk in women.

The conversation explores why Alzheimer's disproportionately affects women at a 2:1 ratio that cannot be explained by longevity alone. Mosconi presents evidence that Alzheimer's begins as a midlife disease in women, with brain changes starting decades before symptoms appear, fundamentally during the menopausal transition.

They discuss Mosconi's groundbreaking brain estrogen receptor imaging technology, the nuanced evidence around menopausal hormone therapy timing and formulations, and her new CARE Initiative - a $50 million research program aimed at cutting women's Alzheimer's risk in half by 2050.

The Personal Journey Into Women's Brain Health Research

Mosconi's research focus stems from personal experience: her grandmother and two great-aunts all developed Alzheimer's disease, with onset in their late 70s and progression over a decade.

The pattern of three sisters developing Alzheimer's while their brother remained unaffected sparked questions about sex-specific risk factors beyond simple aging explanations.

Alzheimer's preclinical phase can last decades, where patients sense cognitive changes but test normally on standard assessments, creating a 'gray area' of subjective awareness without objective diagnosis.

Dementia Types and Women's Disproportionate Alzheimer's Risk

Alzheimer's accounts for 70% of dementia cases, with other forms including frontotemporal dementia (language-focused, earlier onset), Lewy body dementia (alpha-synuclein protein), and vascular dementia often presenting as mixed pathologies.

Only Alzheimer's disease shows the dramatic 2:1 female predominance - other dementias like frontotemporal (more common in men), Lewy body, and vascular dementia show 50:50 gender distribution.

The longevity explanation fails because women don't show higher rates of other age-related diseases like cancer or cardiovascular disease, and the gender lifespan gap is only 2-3 years, not sufficient to explain the disparity.

Brain Imaging Reveals Midlife Origins of Women's Alzheimer's Risk

Mosconi's 2017 study using multiple brain imaging modalities (MRI, PET, spectroscopy) compared premenopausal, perimenopausal, and postmenopausal women with age-matched men.

Before menopause, women's brains showed equivalent or superior metrics to men's brains, but during the menopausal transition, women showed accelerated brain aging markers.

Women with identical symptom severity to men harbor more advanced Alzheimer's pathology in their brains, suggesting they live longer with disease while compensating through higher cognitive reserves.

'Alzheimer's is not a disease of old age, it's a disease of midlife with symptoms that start in old age' - this reframes the critical question to what happens to women in midlife - Lisa

Revolutionary Brain Estrogen Receptor Imaging Technology

Mosconi developed the first brain estrogen receptor imaging using fluorine-18 labeled estradiol that binds to estrogen receptor alpha, allowing quantitative measurement of receptor density.

The tracer, originally developed for oncology to detect breast cancer, crosses the blood-brain barrier via active transporters and accumulates in brain regions with high estrogen receptor density.

Contrary to animal models predicting rapid receptor decline after menopause, human studies show estrogen receptor density remains high until age 65, suggesting extended therapeutic windows.

The brain compensates for declining estradiol by increasing receptor density - 'when estradiol levels come down, there is this compensatory adjustment where the brain will overexpress or make more of these receptors' - Lisa

APOE4 and Genetic Risk Factors Hit Women Harder

Women with one APOE4 copy face 4-fold increased Alzheimer's risk compared to non-carriers, while women with two copies face 12-15 times higher risk.

The genetic risk burden is approximately twice as severe for women compared to men with identical APOE4 genotypes, suggesting sex-specific interactions with genetic susceptibility.

Current Alzheimer's risk prediction models are 'sex-aggregated,' statistically removing gender effects rather than accounting for sex-specific risk factors and interactions.

Menopausal Hormone Therapy: Timing, Formulations, and Evidence

The Women's Health Initiative used oral conjugated equine estrogen with synthetic progestin (MPA) in women averaging 63 years old, far past the optimal therapeutic window.

Meta-analyses of observational studies show 32% reduced Alzheimer's risk for estrogen-only therapy started within 10 years of menopause, and 23% reduction for combined therapy.

Starting hormone therapy more than 10 years after menopause shows no benefit for estrogen-only therapy and increased risk for combined therapy, supporting the 'timing hypothesis.'

Current clinical practice favors transdermal estradiol with micronized progesterone over the oral conjugated estrogens and synthetic progestins used in WHI.

The CARE Initiative: A $50 Million Moonshot for Women's Brain Health

CARE (Cutting Alzheimer's Risk Through Endocrinology) represents the largest research program on women's brain health and menopause ever attempted, funded by Wellcome Leap.

The 3-year initiative aims to prevent 55 million new Alzheimer's cases among women globally by 2050, targeting a 50% risk reduction through neuroendocrine interventions.

CARE will analyze data from over 20 million women across six continents, creating sex-specific risk models that account for reproductive history as a 'vital sign.'

The program includes prospective studies tracking women through hormone therapy initiation using advanced biomarkers rather than waiting decades for clinical outcomes.